231 related articles for article (PubMed ID: 9368551)
1. Generalized efficacy of t-PA for acute stroke. Subgroup analysis of the NINDS t-PA Stroke Trial.
Stroke; 1997 Nov; 28(11):2119-25. PubMed ID: 9368551
[TBL] [Abstract][Full Text] [Related]
2. Intracerebral hemorrhage after intravenous t-PA therapy for ischemic stroke. The NINDS t-PA Stroke Study Group.
Stroke; 1997 Nov; 28(11):2109-18. PubMed ID: 9368550
[TBL] [Abstract][Full Text] [Related]
3. Use of a global test for multiple outcomes in stroke trials with application to the National Institute of Neurological Disorders and Stroke t-PA Stroke Trial.
Tilley BC; Marler J; Geller NL; Lu M; Legler J; Brott T; Lyden P; Grotta J
Stroke; 1996 Nov; 27(11):2136-42. PubMed ID: 8898828
[TBL] [Abstract][Full Text] [Related]
4. Recombinant tissue-type plasminogen activator (Alteplase) for ischemic stroke 3 to 5 hours after symptom onset. The ATLANTIS Study: a randomized controlled trial. Alteplase Thrombolysis for Acute Noninterventional Therapy in Ischemic Stroke.
Clark WM; Wissman S; Albers GW; Jhamandas JH; Madden KP; Hamilton S
JAMA; 1999 Dec; 282(21):2019-26. PubMed ID: 10591384
[TBL] [Abstract][Full Text] [Related]
5. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study (ECASS).
Hacke W; Kaste M; Fieschi C; Toni D; Lesaffre E; von Kummer R; Boysen G; Bluhmki E; Höxter G; Mahagne MH
JAMA; 1995 Oct; 274(13):1017-25. PubMed ID: 7563451
[TBL] [Abstract][Full Text] [Related]
6. Dichotomized efficacy end points and global end-point analysis applied to the ECASS intention-to-treat data set: post hoc analysis of ECASS I.
Hacke W; Bluhmki E; Steiner T; Tatlisumak T; Mahagne MH; Sacchetti ML; Meier D
Stroke; 1998 Oct; 29(10):2073-5. PubMed ID: 9756584
[TBL] [Abstract][Full Text] [Related]
7. Tissue plasminogen activator for acute ischemic stroke.
National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group
N Engl J Med; 1995 Dec; 333(24):1581-7. PubMed ID: 7477192
[TBL] [Abstract][Full Text] [Related]
8. Methods and processes for the reanalysis of the NINDS tissue plasminogen activator for acute ischemic stroke treatment trial.
Hertzberg V; Ingall T; O'Fallon W; Asplund K; Goldfrank L; Louis T; Christianson T
Clin Trials; 2008; 5(4):308-15. PubMed ID: 18697845
[TBL] [Abstract][Full Text] [Related]
9. Lack of clinical significance of early ischemic changes on computed tomography in acute stroke.
Patel SC; Levine SR; Tilley BC; Grotta JC; Lu M; Frankel M; Haley EC; Brott TG; Broderick JP; Horowitz S; Lyden PD; Lewandowski CA; Marler JR; Welch KM;
JAMA; 2001 Dec; 286(22):2830-8. PubMed ID: 11735758
[TBL] [Abstract][Full Text] [Related]
10. A systems approach to immediate evaluation and management of hyperacute stroke. Experience at eight centers and implications for community practice and patient care. The National Institute of Neurological Disorders and Stroke (NINDS) rt-PA Stroke Study Group.
Stroke; 1997 Aug; 28(8):1530-40. PubMed ID: 9259745
[TBL] [Abstract][Full Text] [Related]
11. Findings from the reanalysis of the NINDS tissue plasminogen activator for acute ischemic stroke treatment trial.
Ingall TJ; O'Fallon WM; Asplund K; Goldfrank LR; Hertzberg VS; Louis TA; Christianson TJ
Stroke; 2004 Oct; 35(10):2418-24. PubMed ID: 15345796
[TBL] [Abstract][Full Text] [Related]
12. Intravenous tissue plasminogen activator for acute ischemic stroke: feasibility, safety, and efficacy in the first year of clinical practice.
Chiu D; Krieger D; Villar-Cordova C; Kasner SE; Morgenstern LB; Bratina PL; Yatsu FM; Grotta JC
Stroke; 1998 Jan; 29(1):18-22. PubMed ID: 9445322
[TBL] [Abstract][Full Text] [Related]
13. Time of day, outcome, and response to thrombolytic therapy: the National Institute of Neurological Disorders and Stroke Recombinant Tissue Plasminogen Activator Stroke Trial experience.
Rhoney DH; Coplin WM; Lin Y; Frankel M; Lyden PD; Levine SR
J Stroke Cerebrovasc Dis; 2010 Jan; 19(1):40-8. PubMed ID: 20123226
[TBL] [Abstract][Full Text] [Related]
14. Hyperacute stroke therapy with tissue plasminogen activator.
Alberts MJ
Am J Cardiol; 1997 Aug; 80(4C):29D-34D; discussion 35D-39D. PubMed ID: 9284041
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of tissue plasminogen activator for acute ischemic stroke. NINDS rt-PA Stroke Study Group.
Fagan SC; Morgenstern LB; Petitta A; Ward RE; Tilley BC; Marler JR; Levine SR; Broderick JP; Kwiatkowski TG; Frankel M; Brott TG; Walker MD
Neurology; 1998 Apr; 50(4):883-90. PubMed ID: 9566367
[TBL] [Abstract][Full Text] [Related]
16. The ECASS 3-hour cohort. Secondary analysis of ECASS data by time stratification. ECASS Study Group. European Cooperative Acute Stroke Study.
Steiner T; Bluhmki E; Kaste M; Toni D; Trouillas P; von Kummer R; Hacke W
Cerebrovasc Dis; 1998; 8(4):198-203. PubMed ID: 9684058
[TBL] [Abstract][Full Text] [Related]
17. Recombinant tissue plasminogen activator for minor strokes: the National Institute of Neurological Disorders and Stroke rt-PA Stroke Study experience.
National Institute of Neurological Disorders Stroke rt-PA Stroke Study Group
Ann Emerg Med; 2005 Sep; 46(3):243-52. PubMed ID: 16126134
[TBL] [Abstract][Full Text] [Related]
18. Thrombolysis in acute ischemic stroke.
Luisi A; Hume AL
J Am Board Fam Pract; 1998; 11(2):145-51. PubMed ID: 9542706
[TBL] [Abstract][Full Text] [Related]
19. Effects of tissue plasminogen activator for acute ischemic stroke at one year. National Institute of Neurological Disorders and Stroke Recombinant Tissue Plasminogen Activator Stroke Study Group.
Kwiatkowski TG; Libman RB; Frankel M; Tilley BC; Morgenstern LB; Lu M; Broderick JP; Lewandowski CA; Marler JR; Levine SR; Brott T
N Engl J Med; 1999 Jun; 340(23):1781-7. PubMed ID: 10362821
[TBL] [Abstract][Full Text] [Related]
20. Apolipoprotein E phenotype and the efficacy of intravenous tissue plasminogen activator in acute ischemic stroke.
Broderick J; Lu M; Jackson C; Pancioli A; Tilley BC; Fagan SC; Kothari R; Levine SR; Marler JR; Lyden PD; Haley EC; Brott T; Grotta JC;
Ann Neurol; 2001 Jun; 49(6):736-44. PubMed ID: 11409425
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
